• What type of questions (MCQs, theory, clinical cases)?
• Your level (medical student, postgrad, board exam prep)?

1. Merge them into a single new .pptx (preserving all slides, images, and formatting)
2. Convert the merged file into a PDF

Shorter Regimens for MDR/RR-TB in India (NTEP)

1. BPaLM Regimen (NEW - Preferred, 6 months / 26 weeks)

• Duration: 26 weeks (6 months)
• For: MDR/RR-TB patients without fluoroquinolone resistance
• All-oral regimen - no injectables
• Approved by WHO 2022 guidelines and adopted by NTEP September 2024
• Reduced from the older 9-18 month regimens to just 6 months
• More effective, fewer adverse effects, lower pill burden
• Cost-effective: ICMR analysis showed it saves INR 379 per QALY compared to standard regimen

2. BPaL Regimen (6 months)

• Duration: 6 months
• For: Pre-XDR-TB (MDR/RR-TB with additional fluoroquinolone resistance)
• All-oral, no moxifloxacin (since FQ resistance is present)
• Evidence base: Nix-TB, ZeNix, and TB-PRACTECAL trials

3. 9-11 Month Shorter Oral MDR/RR-TB Regimen (Older regimen, still used)

• Duration: 9-11 months total
• Contraindicated if: Fluoroquinolone resistance, prior use of second-line drugs for >1 month, resistance to key drugs in the regimen
• Now largely replaced by BPaLM as the preferred option

Eligibility Criteria for Shorter Regimens

• Confirmed MDR/RR-TB
• No resistance to fluoroquinolones (moxifloxacin-susceptible)
• No resistance to bedaquiline or pretomanid
• No prior use of bedaquiline or pretomanid for >1 month

• Fluoroquinolone resistance is present (pre-XDR-TB)

Key Monitoring Points

• QTc monitoring - both bedaquiline and moxifloxacin prolong QT interval
• Linezolid toxicity - peripheral neuropathy, optic neuritis, myelosuppression (monitor CBC, visual acuity)
• Hepatotoxicity - liver function tests monthly
• Clofazimine (in 9-11 month regimen) - skin discoloration, GI side effects

Summary Table

Linezolid Duration in the 9-11 Month Shorter MDR-TB Regimen

Full Regimen Breakdown:

Key Points about Linezolid in this regimen:

• Dose: 600 mg daily
• Duration: First 2 months only (not the full intensive phase)
• Dose modification is NOT allowed in this regimen because it is only used for a short 2-month period
• Bedaquiline runs for 6 months (can be extended to 9 months if cultures still positive at month 4)
• High-dose isoniazid runs for 4-6 months

Why only 2 months?

Note: In contrast, in the BPaLM/BPaL regimen, Linezolid is given for the full 6 months.

Official IMNCI Documents - India (MoHFW / NHM)

1. F-IMNCI Chart Booklet (India - NHM/MoHFW)

2. Hospital-Based IMNCI Handbook - 3rd Edition (2024)

Note: This is from Bhutan's MoH but follows the same WHO/UNICEF IMNCI framework used in India.

3. Other Useful Sources

• NHM India - Child Health Guidelines page (for all official IMNCI materials): nhm.gov.in - Child Health Guidelines
• WHO IMCI page (global reference): who.int/IMCI

Important Note

• Summarize any specific section (e.g., danger signs, pneumonia classification, diarrhea management)
• Create a quick-reference chart on any IMNCI topic

Latest India IMNCI Documents (MoHFW/NHM 2023)

For Medical Officers:

For Health Workers:

F-IMNCI Chart Booklet (2023) - Latest Version:

IMNCI Interview Questions & Answers

Based on IMNCI Participant Module for Medical Officers (MoHFW, India 2023)

1. BASICS & OVERVIEW

• Young infant: Birth to 2 months
• Sick child: 2 months to 5 years

2. GENERAL DANGER SIGNS (2 months - 5 years)

1. Not able to drink or breastfeed
2. Vomits everything
3. Lethargic or unconscious
4. Convulsions (now or in this illness)

3. COUGH / DIFFICULT BREATHING

• PINK (Severe Pneumonia): Chest in-drawing OR any general danger sign → Urgent referral + first dose antibiotics
• YELLOW (Pneumonia): Fast breathing only → Oral amoxicillin 5 days + follow-up in 2 days
• GREEN (No Pneumonia): No fast breathing, no chest in-drawing → Home care, soothe throat

4. DIARRHOEA

• Restless/irritable
• Sunken eyes
• Drinks eagerly/thirsty
• Skin pinch goes back slowly

• Lethargic/unconscious
• Sunken eyes
• Not able to drink/drinks poorly
• Skin pinch goes back very slowly (>2 seconds)

• Plan A - No dehydration: Home ORS, continue feeding
• Plan B - Some dehydration: 75 ml/kg ORS over 4 hours in facility
• Plan C - Severe dehydration: IV fluids urgently (Ringer's Lactate)

• < 6 months: 10 mg/day for 14 days
• ≥ 6 months: 20 mg/day for 14 days

5. FEVER

• High malaria risk area: Positive RDT/smear = Malaria; treat with ACT
• Low malaria risk: If no obvious cause = Fever malaria unlikely → investigate for other causes

6. EAR PROBLEMS

• Mastoiditis: Tender swelling behind ear → PINK referral
• Acute ear infection: Pus discharge <14 days / ear pain → Oral amoxicillin 5 days + dry wicking
• Chronic ear infection: Pus discharge ≥14 days → Dry wicking only, no antibiotics systemically
• No ear infection: No signs

7. MALNUTRITION & ANAEMIA

• SAM (Severe Acute Malnutrition): Visible severe wasting OR oedema of both feet OR MUAC <115 mm → PINK referral to NRC
• MAM (Moderate Acute Malnutrition): MUAC 115-125 mm OR weight-for-height -2 to -3 SD → YELLOW, RUTF/food supplementation
• Normal: MUAC >125 mm

• Severe anaemia: Palmar pallor + very pale palms → PINK referral
• Some anaemia: Palmar pallor only → Iron + folic acid for 14 days
• No anaemia: No pallor

• <1 year: Not given
• 1-2 years: Half tablet (200 mg)
• ≥2 years: One tablet (400 mg)

8. YOUNG INFANT (Birth - 2 months)

• Not feeding well
• Convulsions
• Fast breathing ≥ 60/min
• Severe chest in-drawing
• Fever (≥37.5°C) or Hypothermia (<35.5°C)
• Movement only when stimulated / No movement at all
• Umbilical redness extending to skin / deep skin pustules

• Severe jaundice: Yellow palms/soles → PINK, phototherapy/exchange transfusion
• Jaundice: Yellow skin not yet at palms/soles → Follow up in 1 day
• No jaundice

9. COLOUR-CODED CLASSIFICATION SYSTEM

10. IMMUNISATION & VITAMIN A

• Measles: Give Vitamin A immediately
• SAM: Part of management
• Routine: Every 6 months from 6 months to 5 years

11. FOLLOW-UP INTERVALS

12. COUNSELLING (MOTHER)

1. Feeding - Breastfeeding, complementary feeding advice
2. Fluids - Increase fluids during illness
3. When to return - Immediately if danger signs appear
4. Mother's own health - Assess and refer if needed

• Cannot drink or feed
• Becomes sicker
• Develops fever (or fever continues)
• Blood in stool
• Breathing becomes difficult

FOBT - Fecal Occult Blood Test

Definition

Types of FOBT

1. Guaiac-based FOBT (gFOBT) - "Chemical method"

2. Fecal Immunochemical Test (FIT / iFOBT) - "Immunological method"

3. Stool DNA Test (MT-sDNA / FIT-DNA / Cologuard)

• Combines FIT with detection of altered DNA markers (KRAS mutations, methylation)
• Higher sensitivity, lower specificity
• Done every 1-3 years

Key Comparison: gFOBT vs FIT

Primary Use - Colorectal Cancer (CRC) Screening

• Target population: Average-risk adults ≥ 45-50 years (USPSTF recommends from age 45)
• Frequency: Annually (gFOBT or FIT)
• Screening reduces CRC mortality by 15-33% (large RCTs)
• Cancers detected at earlier stage in screened populations
• NOT useful for adenoma screening alone (small polyps don't bleed regularly)

Other Uses of FOBT

• Suspected occult GI bleeding (iron deficiency anemia workup)
• Follow-up after treatment of colorectal cancer
• Investigating unexplained iron deficiency

Limitations of gFOBT

1. False Positives caused by:
   • Red/processed meat (animal heme)
   • Raw vegetables (plant peroxidases - broccoli, turnips, horseradish)
   • NSAIDs / Aspirin (cause GI bleeding)
   • Iron supplements
   • Upper GI bleeding (gastric ulcer, esophageal varices)
2. False Negatives caused by:
   • High-dose Vitamin C (inhibits guaiac reaction)
   • Intermittent/non-bleeding tumors
   • Degradation of blood during transit
3. Up to 80% of patients with positive FOBT have negative colonoscopy

What Happens After a Positive FOBT?

Important Numbers to Remember

Exam High-Yield Points

• gFOBT detects heme (any source) - FIT detects human hemoglobin specifically
• FIT has no dietary restrictions - gFOBT requires dietary restrictions
• FOBT is a screening tool, not diagnostic - positive test always requires colonoscopy
• Gold standard for CRC screening = Colonoscopy
• FOBT reduces CRC mortality, not incidence
• Annual FOBT is equivalent to colonoscopy every 10 years in average-risk patients (as part of a screening program)

FOBT Screening Criteria - Who to Screen & When

1. AVERAGE RISK - Standard Eligibility

• Prior diagnosis of colorectal cancer (CRC) or adenomatous polyps
• Inflammatory bowel disease (Crohn's / Ulcerative Colitis)
• Personal or family history of Lynch syndrome or FAP
• Strong family history of CRC

Screening Start Age (by guideline):

Key update: Age lowered from 50 to 45 years across all major guidelines (ACS 2018, USPSTF 2021) due to rising CRC incidence in younger adults.

FOBT Frequency for Average Risk:

2. HIGH RISK - Earlier / More Frequent Screening

Note: High-risk individuals should have colonoscopy, not just FOBT.

3. CRITERIA TO STOP SCREENING

4. CONTRAINDICATIONS / WHO SHOULD NOT GET FOBT

• Patients with active symptoms (rectal bleeding, change in bowel habits, weight loss) - go directly to colonoscopy, FOBT not indicated
• Patients with known CRC or polyps - need colonoscopy follow-up, not FOBT
• Patients with life expectancy < 10 years - screening not beneficial
• Patients with IBD - colonoscopy with biopsies preferred

5. WHAT HAPPENS AFTER A POSITIVE FOBT

Positive FOBT → Colonoscopy (mandatory)
                ↓
        If colonoscopy negative → No further workup for occult blood
        If colonoscopy positive → Treat accordingly

• Harrison's Principles 22e states: "A positive test necessitates colonoscopy. If evaluation of the colon is negative, further workup is not recommended unless iron-deficiency anemia is present."

6. QUICK SUMMARY TABLE